ProCE Banner Activity

Optimizing Outcomes for Relapsed/Refractory CLL/SLL and MCL

Slideset

Download this slideset featuring expert perspectives on the latest in BTK inhibitor therapy for patients with relapsed/refractory CLL and MCL.

Released: October 30, 2023

Expiration: October 29, 2024

Share

Faculty

Kami Maddocks

Kami Maddocks, MD

Professor-Clinical, Division of Hematology
Director, Lymphoma Program
Associate Division Director for Ambulatory Operations, Division of Hematology
Medical Director, Infusion Services
Associate Chief Medical Officer, The James Cancer Hospital
Chief of Staff – Elect, The James Cancer Hospital
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Jennifer A. Woyach

Jennifer A. Woyach, MD

D. Warren Brown Professor of Leukemia Research
Division of Hematology
The Ohio State University
Columbus, Ohio

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly